Trending...
- Author Deric Whaley's book 'The Ride' gives unique insider view on prison life
- Agency EA Appoints Dee Hall to Board of Directors
- Enable Accessible Haircare Wins Bronze at 2025 NACD Packaging Awards
CHENGDU, China, April 24, 2025 ~ Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (6990.HK) has announced that it will be showcasing the results of six clinical studies at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago from May 30 to June 3. These studies, led by Kelun, include data from their TROP2 antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT), anti-PD-L1 mAb tagitanlimab, and RET inhibitor KL590586 (A400/EP0031).
The abstracts for these studies will be published on ASCO's official website on May 22, 2025, local time. The selected studies for ASCO 2025 are focused on various types of cancer and aim to present promising treatment options for patients.
One of the studies, titled "Sacituzumab tirumotecan (sac-TMT) in patients with previously treated advanced EGFR-mutated non-small cell lung cancer (NSCLC): Results from the randomized OptiTROP-Lung03 study," will be presented as an oral presentation on June 1st. This study focuses on the use of sac-TMT as a potential treatment option for patients with advanced NSCLC.
More on illi News
Another study, titled "Tagitanlimab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (R/M NPC): Results from a randomized, double-blind, phase 3 study," will also be presented as an oral presentation on May 31st. This study looks at the effectiveness of tagitanlimab in combination with other treatments for patients with recurrent or metastatic nasopharyngeal carcinoma.
The Phase II OptiTROP-Breast05 study will also be presented as a rapid oral presentation on May 30th. This study focuses on the use of sac-TMT as a first-line treatment for unresectable locally advanced/metastatic triple-negative breast cancer (a/m TNBC).
In addition to these presentations, there will also be a poster presentation on May 31st for the study titled "Sacituzumab tirumotecan (sac-TMT) in combination with tagitanlimab (anti-PD-L1) in first-line (1L) advanced non-small-cell lung cancer (NSCLC): Non-squamous cohort from the phase II OptiTROP-Lung01 study." This study looks at the potential of combining sac-TMT and tagitanlimab as a first-line treatment option for patients with advanced NSCLC.
More on illi News
The remaining two studies, "Sacituzumab Tirumotecan (sac-TMT) in patients (pts) with previously treated locally advanced or metastatic (LA/M) non-small cell lung cancer (NSCLC) harboring uncommon EGFR mutations: Preliminary results from a phase 2 study" and "Results from a phase I study of KL590586 in patients with advanced RET-mutant medullary thyroid cancer," will both be presented as poster presentations on May 31st and June 2nd respectively.
These studies demonstrate Kelun's commitment to developing innovative treatments for various types of cancer. The results presented at ASCO 2025 have the potential to significantly impact the lives of patients and improve their outcomes. The company looks forward to sharing their findings with the medical community at this prestigious event.
The abstracts for these studies will be published on ASCO's official website on May 22, 2025, local time. The selected studies for ASCO 2025 are focused on various types of cancer and aim to present promising treatment options for patients.
One of the studies, titled "Sacituzumab tirumotecan (sac-TMT) in patients with previously treated advanced EGFR-mutated non-small cell lung cancer (NSCLC): Results from the randomized OptiTROP-Lung03 study," will be presented as an oral presentation on June 1st. This study focuses on the use of sac-TMT as a potential treatment option for patients with advanced NSCLC.
More on illi News
- Pulitzer Prize Nominated Lauren Coyle Rosen Releases New Album, Covers and Veils in Blue
- Detroit Grand Prix High Profile Media Exposure, $100 Million Financing for Major Acquisition & Growth Strategy; Remote Lottery Platform: Lottery.com
- Tomorrow's World Today Shines Bright with Four Telly Awards at the 46th Annual Telly Awards
- AbbVie Partners with Chicago Cubs on "Striking Out Cancer"
- Chicago: Mayor Brandon Johnson, City Officials, Lamar Johnson Collaborative, and 548 Development Attend Groundbreaking of Mixed-Use West Humboldt Park Development
Another study, titled "Tagitanlimab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (R/M NPC): Results from a randomized, double-blind, phase 3 study," will also be presented as an oral presentation on May 31st. This study looks at the effectiveness of tagitanlimab in combination with other treatments for patients with recurrent or metastatic nasopharyngeal carcinoma.
The Phase II OptiTROP-Breast05 study will also be presented as a rapid oral presentation on May 30th. This study focuses on the use of sac-TMT as a first-line treatment for unresectable locally advanced/metastatic triple-negative breast cancer (a/m TNBC).
In addition to these presentations, there will also be a poster presentation on May 31st for the study titled "Sacituzumab tirumotecan (sac-TMT) in combination with tagitanlimab (anti-PD-L1) in first-line (1L) advanced non-small-cell lung cancer (NSCLC): Non-squamous cohort from the phase II OptiTROP-Lung01 study." This study looks at the potential of combining sac-TMT and tagitanlimab as a first-line treatment option for patients with advanced NSCLC.
More on illi News
- ILLINOIS TEAMSTERS DEMAND LAWMAKERS PREVENT CATASTROPHIC CUTS TO PUBLIC TRANSPORTATION
- 6 Love Sports and Eight Sleep Announce Partnership Miami Women's Padel League Rebranded as the Eight Sleep Miami Women's Padel League by 6 Love Sports
- The TOBU RAILWAY X COFFEE PROJECT Supports Nikko Tourism and Fosters English Speaking Guides, Through November 27, 2026
- Al-Tabbaa & Hackett: Fixed Rates Improve For Savers
- Zeigler Auto Group Earns its 12th Chicago's Best & Brightest Companies To Work For® Award
The remaining two studies, "Sacituzumab Tirumotecan (sac-TMT) in patients (pts) with previously treated locally advanced or metastatic (LA/M) non-small cell lung cancer (NSCLC) harboring uncommon EGFR mutations: Preliminary results from a phase 2 study" and "Results from a phase I study of KL590586 in patients with advanced RET-mutant medullary thyroid cancer," will both be presented as poster presentations on May 31st and June 2nd respectively.
These studies demonstrate Kelun's commitment to developing innovative treatments for various types of cancer. The results presented at ASCO 2025 have the potential to significantly impact the lives of patients and improve their outcomes. The company looks forward to sharing their findings with the medical community at this prestigious event.
Filed Under: Business
0 Comments
Latest on illi News
- Naperville: Cook County Convicted Felon Charged with Alleged Illegal Possession of Four Loaded Firearms
- This Artificial Intelligence Platform Could Change How Hollywood Gets Funded Forever
- Chicago: Mayor Johnson Announces $20 Million in Grant Awards for Community Development Projects
- $100 Million Financing Unlocked for Aggressive Acquisition and Growth Strategy Including Plan to Acquire Remote Lottery Platform: Stock Symbol: LTRY
- ARCH Dental + Aesthetics Unveils New Website for Enhanced Patient Experience
- GO2 Partners Named to PPAI 100 List
- Illumina expands clinical oncology portfolio unlocking new standard of care and access to precision therapies
- B&M Life Center Launches Urgent Fundraiser to Support Homeless and Impoverished in Greater Chicago
- The Future of Commerce Summit Returns to TECHICAGOWEEK 2025 with Innovation, AI and Entrepreneurship
- Chicago: ICYMI: Mayor Brandon Johnson Launches Summer Sports Series to Provide Safe Spaces During Holiday Weekends
- Juventix Regenerative Medical Announces Strategic Partnership with Juvasonic® to Expand Needle-Free Biologic Delivery Platform
- Agency EA Appoints Dee Hall to Board of Directors
- Discovering Cindy Crawford with Marie P. Anderson on The Isaiah Grass Show
- Prymax Media & Technology Group Acquires 'Hidden Treasures' From Estate of Jewel Records Founder Stan Lewis
- Mentor Agile Offers $0 Tuition Product Owner Training for WIOA-Approved Candidates in Chicago
- Midwest Pond Features Launches Seasonal Cleanout Services Across Chicagoland
- PHILLIPS LYTLE EXPANDS CHICAGO OFFICE TO FUEL MIDWEST GROWTH PLANS
- Cooking with the Godfather Blends Family Tradition, Italian Flavor, and Leadership Wisdom
- Group Seeks End to Mandated Community Psychiatric Programs, Citing Global Alarm
- CoreIntegrator Announces Sage Intacct Approved A/P One Integration, Becoming an Official Sage Partner